Name:

Vaxigrip

Abbreviation:

TIV (Trivalent Inactivated Vaccine) or QIV (Quadrivalent Inactivated Vaccine) - depending on the specific formulation.

General Overview:

Vaxigrip is an inactivated, subunit vaccine that contains purified surface antigens. It is produced from inactivated influenza viruses and undergoes specialized processing to ensure antigen purity and stability.

The vaccine's formulation is updated annually based on recommendations from the World Health Organization (WHO) and global epidemiological surveillance data to ensure alignment with circulating viral strains. It is available in both trivalent and quadrivalent forms, providing a broad spectrum of immune protection.

Vaxigrip is supplied in pre-filled syringes, simplifying administration, ensuring accurate dosing, and reducing the risk of administration errors. The formulation does not contain adjuvants, enhancing its tolerability across various age groups.

The vaccine is stored at a temperature range of 2°C to 8°C and must be protected from freezing to maintain its stability and effectiveness throughout its shelf life.

The immunogenicity and safety of Vaxigrip have been well established through numerous clinical studies.